SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment shares are trending following the company's fiscal first-quarter earnings report, which featured a revenue and earnings beat alongside a record funded backlog of $1.5 billion. While the community is debating whether the current market environment and cautious guidance justify the company's valuation, sentiment remains extremely bullish regarding the company's long-term leadership in drone and laser weapon technology.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as traders debate a proposed midterm stimulus promise, with significant skepticism regarding its fiscal viability and the company's financial performance. Community discussion remains highly polarized, focusing on criticisms of the proposed dividend, geopolitical tensions, and broader concerns over national debt and market stability.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Compass Pathways is trending following positive clinical developments, including a recent partnership with the U.S. Department of Veterans Affairs and successful trial results for its psilocybin treatment, COMP360. Investors are reacting to these milestones, the upcoming NDA submission, and potential FDA approval, while debating the stock's valuation relative to its industry peers.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta shares are trending due to the official launch of Muse, an autonomous AI personal assistant, which traders are evaluating as a potential revenue-generating catalyst for the company. Community sentiment remains divided, with supporters highlighting the product's integration across Meta's app ecosystem, while others express skepticism regarding the company's aggressive infrastructure spending and the long-term monetization of its AI initiatives.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors react to the company's annual product launch, which featured the debut of the high-end, foldable iPhone Duo alongside the iPhone 18 Pro lineup. The community is split between bullish sentiment over the hardware's potential to drive a new revenue cycle and skepticism regarding the device's high price point and late entry into the foldable market.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Traders are closely watching Oracle's upcoming earnings, with sentiment split between bullish expectations for cloud-driven growth linked to AI demand and significant concerns regarding the company's capital expenditures and debt levels. Many investors are anticipating a volatile reaction, with some positioning for a post-earnings rally while others warn of potential downside if guidance fails to reassure the market about infrastructure spending.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is trending following strong Phase 2 data for its ABCL635 menopause drug and a subsequent oversubscribed equity offering. The community is focused on the potential for a Phase 3 trial and future partnerships, with significant enthusiasm around recent open-market insider purchases signaling management confidence.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing downward pressure following the release of Phase 3 IZAR-1 trial data, which traders and analysts describe as competitive but lacking clear superiority over existing biologics. Investor sentiment is further weighed down by the company's mixed shelf filing, which has fueled speculation about future dilution, though some long-term holders continue to emphasize the potential for best-in-class performance in hidradenitis suppurativa and the upcoming BLA submission.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending primarily due to the announcement of a strategic partnership with Nebius Group, which designates Nebius as a preferred sovereign AI infrastructure provider. While the community is debating this catalyst, sentiment remains divided between bulls focused on long-term AI growth and bears highlighting concerns over high valuation and persistent short-selling pressure.

Maase, Inc. operates as a integrated provider and operator of artificial intelligence (AI) centric full-scene digital systems. The firm focus on areas of flexible energy deployment and intelligent commercial network operation, and provide closed-loop solutions from computing infrastructure, smart hardware and full-scene services, aiming to achieve large-scale implementation of AI technologies across industries. The company was founded by Hai Feng Yu on August 6, 2018 and is headquartered in Qingdao, China.

Maase Inc. - Ordinary Shares - Class A

Highest Performances Holdings Inc. - ADR

MAAS is receiving significant attention as the community tracks its transition into an AI infrastructure provider, specifically focusing on its recent contract wins, development of mobile charging robotics, and strategic partnerships in the energy-compute sector. Traders are debating the company's long-term commercial execution against its history of volatility, with many watching for sustained volume and follow-through on enterprise-level deployments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ PR Newswire NEW YORK, Sept. 3, 2026 NEW YORK, Sept. 3, 2026 /PRNewswire...

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of +15.70% and +148.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline

LENZ Therapeutics, Inc. (LENZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oversold Conditions For Lenz Therapeutics (LENZ)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -20.00% and +15.21%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

HC Wainwright Expects Weaker Earnings for LENZ Therapeutics

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Analysts at HC Wainwright reduced their Q1 2026 earnings estimates for LENZ Therapeutics in a research note issued to investors on Tuesday, April...

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm...

• Reported GAAP EPS of -$1.02 down -92.45% YoY
• Reported revenue of $5.49M up 9.72% YoY

LENZ Therapeutics faces significant risks from its limited operating history, total reliance on a single product, and dependence on third-party manufacturers for the commercial supply of its only approved product.

LENZ Therapeutics benefits from the unique FDA-approved status of VIZZ, a robust international licensing strategy across multiple global territories, and a solid cash position to fund ongoing commercialization and operations.

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

LENZ Therapeutics Inc.

Bearish Sentiment

Yes, day one

Yes, but I'll wait for reviews

No, too expensive

No, not interested in a foldable

Apple unveiled its first foldable iPhone, reportedly called the iPhone Duo, at its September 9 event, with pricing starting at $2,000 for the 256GB model. Will you buy the $2,000 iPhone Duo? Vote and explain your reasoning in the comments.

Apple ($AAPL) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Stocktwits

) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Current Price	$4.91
Prev Close	$5.33
Open	$5.31
Dividend Yield	0.00%
50-Day Moving Average	$5.26
Beta	1.53
Avg. Volume	735,886.00
PE Ratio	-1.20

52-Week High	$50.40
52-Week Low	$4.54
Market Capitalization	$167.47M
EPS (Annual)	-$2.85
Price to Book	0.70
Revenue Per Employee	$125,578.95

Feed

News

Sentiment

Earnings

Fundamentals

Info

LENZ Fundamentals